Among them, mycalamide A (Myc A) and B (Myc B) have shown their potent antiproliferative activity in cancer models both in vitro and in vivo, including leukemia, lung, pancreatic and colon carcinomas, ovarian sarcoma, melanoma, and lymphoma [103,137], and reviewed by Mosey and Floreancig [104]. Here, MYC is linked to lymphoma.